4LSC2533 [D9]-Dabrafenib

Dabrafenib (GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth.

Stable isotope labeled Dabrafenib is intended for use as an internal standard for the quantification of Dabrafenib by LC or GC-mass spectrometry.

If the number, nature and/or location of stable isotope label atoms (D, ¹⁵N, ¹³C) in this molecule don’t fit with your application, don’t hesitate to contact us to discuss your specific needs.

Keywords:

Stable isotope labeled active pharmaceutical ingredient (API), stable isotope dilution analysis, internal standard, stable isotope labeled standard (SIL), therapeutic drug monitoring (TDM), quantitative bioanalytical method validation, clinical diagnosis, LC/MS method validation, quantitative proteomics, selective reaction monitoring (SRM), multiple reaction monitoring (MRM), peptide based quantitative proteomics, custom stable isotope labeled (SIL) peptide, diagnostic breath test, clinical chemistry, diagnostic tools & biomarkers.

• Molecular Formula: C₂₃H₁₁D₉F₃N₅O₂S₂
• Molecular Weight: 528.62 g/mol
• Specification:
  Minimum chemical purity: 95.0 %
  Minimum Isotopic Enrichment: ²H ≥98 %
• Solubility: Methanol (MeOH), Dimethylsulfoxide (DMSO),
• HS Code: 284590

N/A